성매개감염 진료지침 2023

2. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010;65:2141-8.
3. Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrob Agents Chemother 2019;63:e01644-18.
4. Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill 2018; 23(27). doi: 10.2807/1560-7917. ES.2018.23.27.1800323.
5. Fifer H, Natarajan U, Jones L, et al. Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. N Engl J Med 2016; 374(25): 2504-2506. doi: 10.1056/ NEJMc1512757.
6. Chen SC, Yin YP, Dai XQ, et al. First nationwide study regarding ceftriaxone resistance and molecular epidemi- ology of Neisseria gonorrhoeae in China. J Antimicrob Chemother 2016; 71(1): 92-99. doi: 10.1093/jac/dkv321.
7. Peng T, Lin H, Liu Q, et al. Ceftriaxone susceptibility and molecular characteristics of Neisseria gonorrhoeae isolates in Changsha, China. J Infect Chemother 2017; 23(6): 385–389. doi: 10.1016/j. jiac.2017.03.007.
8. Town K, Obi C, Quaye N, et al. Drifting towards ceftri- axone treatment failure in gonorrhoea: risk factor analy- sis of data from the Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales. Sex Transm Infect 2017; 93(1): 39-45. doi: 10.1136/ sextrans-2016-052583.
9. Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone- Resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis 2018; 24(2) doi: 10.3201/eid2402.171756.
10. Camara J, Serra J, Ayats J, et al. Molecular characteri- zation of two high-level ceftriaxone- resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012; 67(8): 1858-1860. doi: 10.1093/jac/dks162.
11. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful inter- national clone causes treatment failure. Antimicrob Agents Chemother 2012; 56(3): 1273-1280. doi: 10.1128/ AAC.05760-11.
12. Whiley DM, Jennison A, Pearson J, et al. Genetic char- acterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin. Lancet Infect Dis 2018; 18(7): 717-718. doi: 10.1016/ S1473-3099(18)30340-2.
13. Lahra MM, Martin I, Demczuk W, et al. Cooperative Recognition of Internationally Disseminated Ceftriaxone- Resistant Neisseria gonorrhoeae Strain. Emerg Infect Dis 2018; 24(4). doi: 10.3201/ eid2404.171873.
14. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65(10): 2141-2148. doi: 10.1093/ jac/dkq289.

<PAGE>108